

The success of **Continuous Tableting**

begins with a Research and Development focus



The path to commercialization of your drug product begins on day 1 of development and Hovione's pragmatic approach ensures the viability of the entire manufacturing process.

Drive your development with our in-house experts

At Hovione, we are experienced in understanding the most critical formulation and process parameters using the least amount of valuable API, which is typically scarce in the early phases of drug product development.

Dedicated R&D labs, staffed by passionate minds, host a range of process development capabilities and manufacturing solutions, while following a Quality-by-Design (QbD) approach. We first develop the unit operations of the continuous process individually, leveraging a sound portfolio of modeling tools, then assess the risk of transfer to the Continuous Tableting line, reducing unnecessary use of API's.

Our R&D scientific expertise





Hovione has installed state-of-the-art Continuous Tableting equipment

Quality is the focus at every stage of drug product development

At Hovione, we have the scientific know-how and tools to identify and mitigate risks early in development, as well as to correct the process trajectory through in-line diversion points or advanced process models during manufacturing, and we will work with you on the best strategy to manage these tools throughout the product lifecycle.


Secure commercial transfer with a trusted partner

At Hovione we collaborate with our customers to ensure that the transition from development to commercial supply is robust through a rigorous risk-based approach and applied relevant design spaces.

Our commercial manufacturing platform is equipped to support key control needs and delivers on operational excellence, mechanistic modeling, and appropriate Process Analytical Technology (PAT). The Hovione quality system is designed to support the release of Continuous Tableting products through automated in-process controls, deployment of real time release, and a compliant digital infrastructure.

Key control strategy elements

- Risk assessment
- Modeling
- Funnel plot analysis
- Residence time distribution
- Diversion strategy
- Material tracking
- Real time release testing



Find out today if Continuous Tableting is right for your product.

Count on our experts to provide guidance and help decide the best path for your drug product.

www.hovione.com hello@hovione.com

In the United States, call 1 609-918-2600 In Europe and the rest of the world, call +351 21 982 9000



CDMO

AWARDS 2023

CDMO

AWARDS 2023

These lists are not to be construed as a representation of non-infringement or as an offer to sell in those countries where such would constitute an infringement of third parties' patent rights.

The content of this current brochure is subject to change without notice and does not constitute a contractual offer to buy or sell products, services or knowledge.

CDMO

CDMO

CDMO





© Hovione October 2023

